Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy Jurnal Penyakit Dalam Indonesia
Citrawijaya, Henrico
Unknown Affiliation
Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
The Role of Paternal History of Type 2 Diabetes Mellitus on Prediabetes Status among The Offspring of Type 2 Diabetes Mellitus Patients Ekaputri, Maulidia; Citrawijaya, Henrico; Sudirman, Adrian Reynaldo; Jonathan, Kevin; Murti, Radityo Alu; Balqis, Ayu Putri; Purnamasari, Dyah
Jurnal Penyakit Dalam Indonesia Vol. 6, No. 4
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Evidence-Based Case Report: Comparison of Potassium Competitive Acid Blocker and Proton Pump Inhibitor as First Line Therapy in Adult Patients with H. pylori Infection Mustikarani, Dewi; Citrawijaya, Henrico; Nursyirwan, Saskia Aziza
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 25, No 2 (2024): VOLUME 25, NUMBER 2, August, 2024
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/2522024%p

Abstract

ABSTRACTBackground: Increased eradication of Helicobacter pylori decreases the incidence of gastric cancer. Vonoprazan is a potassium-competitive acid blocker (PCAB) with a stronger acid production suppression effect than proton pump inhibitors (PPI). Vonoprazan has been recognized as a therapy for gastric acid reflux disease since 2015 in Japan, but the comparison of the effectiveness of PCAB first-line therapy with PPI for adult patients with H. pylori infection is still controversial.Method: A literature search was carried out on three databases: Pubmed, Cochrane, and Scopus on March 30th 2023, using keywords vonoprazan, potassium competitive acid blocker (PCAB), proton pump inhibitor, and H. pylori. There were 7 studies on Pubmed, 26 studies on Cochrane, and 144 studies on Scopus. Critical screening was conducted using the Oxford Centre for Evidence-Based Medicine for systematic reviews and randomized controlled trials. Results: Based on screening of inclusion and exclusion criteria, one study met the criteria. The intention to treat analysis (ITT) showed eradication of H. pylori in the combination of three therapies with PCAB vs PPI of 91.81% vs 75.5% (1,18 [1.08−1.28], p0,0001), no heterogeneity found (I2 = 43%). Analysis per protocol showed PCAB versus PPI eradications of 92.99% vs 78.57% (1,13 [1,02−1,26], p = 0.02), heterogeneity obtained (I 2 = 75%). Conclusion: Generally, PCAB has better eradication than PPI as first-line therapy for adult patients with H. pylori infection Keywords: potassium competitive acid blocker, proton pump inhibitors, helicobacter pylori
Co-Authors Balqis, Ayu Putri Dyah Purnamasari Ekaputri, Maulidia Jonathan, Kevin Murti, Radityo Alu Mustikarani, Dewi Saskia Aziza Nursyirwan, Saskia Aziza Sudirman, Adrian Reynaldo